VERIFY the role of initial combination therapy in patients with type 2 diabetes

Lancet. 2019 Oct 26;394(10208):1483-1485. doi: 10.1016/S0140-6736(19)32165-8. Epub 2019 Sep 18.

Authors

Ofri Mosenzon¹, Gil Leibowitz²

Affiliations

¹ Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: ofrim@hadassah.org.il.
² Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

PMID: 31542294
DOI: 10.1016/S0140-6736(19)32165-8

No abstract available

Publication types

Comment

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2*
Double-Blind Method
Humans
Hypoglycemic Agents
Metformin*
Vildagliptin

Substances

Blood Glucose
Hypoglycemic Agents
Metformin
Vildagliptin